169 related articles for article (PubMed ID: 24986420)
1. Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways.
Axelrod MJ; Mendez RE; Khalil A; Leimgruber SS; Sharlow ER; Capaldo B; Conaway M; Gioeli DG; Weber MJ; Jameson MJ
Head Neck; 2015 Dec; 37(12):1722-32. PubMed ID: 24986420
[TBL] [Abstract][Full Text] [Related]
2. Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.
Shin DH; Lee HJ; Min HY; Choi SP; Lee MS; Lee JW; Johnson FM; Mehta K; Lippman SM; Glisson BS; Lee HY
J Natl Cancer Inst; 2013 Oct; 105(20):1558-70. PubMed ID: 24092920
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
[TBL] [Abstract][Full Text] [Related]
5. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
[TBL] [Abstract][Full Text] [Related]
6. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.
Jameson MJ; Beckler AD; Taniguchi LE; Allak A; Vanwagner LB; Lee NG; Thomsen WC; Hubbard MA; Thomas CY
Mol Cancer Ther; 2011 Nov; 10(11):2124-34. PubMed ID: 21878657
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
[TBL] [Abstract][Full Text] [Related]
8. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.
Shin DH; Min HY; El-Naggar AK; Lippman SM; Glisson B; Lee HY
Mol Cancer Ther; 2011 Dec; 10(12):2437-48. PubMed ID: 21980128
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation.
Wilsbacher JL; Zhang Q; Tucker LA; Hubbard RD; Sheppard GS; Bamaung NY; Fidanze SD; Wang GT; Hu X; Davidsen SK; Bell RL; Wang J
J Biol Chem; 2008 Aug; 283(35):23721-30. PubMed ID: 18559346
[TBL] [Abstract][Full Text] [Related]
10. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
[TBL] [Abstract][Full Text] [Related]
11. IGF1R and Src inhibition induce synergistic cytotoxicity in HNSCC through inhibition of FAK.
Lehman CE; Spencer A; Hall S; Shaw JJP; Wulfkuhle J; Petricoin EF; Bekiranov S; Jameson MJ; Gioeli D
Sci Rep; 2021 May; 11(1):10826. PubMed ID: 34031486
[TBL] [Abstract][Full Text] [Related]
12. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
Lin YC; Wu MH; Wei TT; Chuang SH; Chen KF; Cheng AL; Chen CC
Neoplasia; 2012 Jun; 14(6):463-75. PubMed ID: 22787428
[TBL] [Abstract][Full Text] [Related]
13. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
Haluska P; Carboni JM; TenEyck C; Attar RM; Hou X; Yu C; Sagar M; Wong TW; Gottardis MM; Erlichman C
Mol Cancer Ther; 2008 Sep; 7(9):2589-98. PubMed ID: 18765823
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma.
Slomiany MG; Black LA; Kibbey MM; Tingler MA; Day TA; Rosenzweig SA
Cancer Lett; 2007 Apr; 248(2):269-79. PubMed ID: 16996205
[TBL] [Abstract][Full Text] [Related]
15. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
16. IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas.
Wang Q; Zhang Y; Zhu J; Zheng H; Chen S; Chen L; Yang HS
Signal Transduct Target Ther; 2020 Aug; 5(1):153. PubMed ID: 32843616
[TBL] [Abstract][Full Text] [Related]
17. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
[TBL] [Abstract][Full Text] [Related]
18. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
Young NR; Liu J; Pierce C; Wei TF; Grushko T; Olopade OI; Liu W; Shen C; Seiwert TY; Cohen EE
Mol Oncol; 2013 Jun; 7(3):359-68. PubMed ID: 23200321
[TBL] [Abstract][Full Text] [Related]
19.
Anisuzzaman AS; Haque A; Wang D; Rahman MA; Zhang C; Chen Z; Chen ZG; Shin DM; Amin AR
Mol Cancer Ther; 2017 Apr; 16(4):729-738. PubMed ID: 28119490
[TBL] [Abstract][Full Text] [Related]
20. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
Warshamana-Greene GS; Litz J; Buchdunger E; Hofmann F; García-Echeverría C; Krystal GW
Mol Cancer Ther; 2004 May; 3(5):527-35. PubMed ID: 15141010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
